Stoke Therapeutics Inc.

STOK | NASDAQ

Price Alert Chart Builder DCF Calculator

$28.05

-$0.38 (-1.34%)

At close: Sep 21, 2026, 4:00 PM ET

$27.66

-$0.39 (-1.39%)

After-hours: Sep 21, 2026, 7:54 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.34%

(1D)

Rating

Updated: Aug 20, 2026

40.6

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $1.81B

1D Range

27.74 28.65

52W Range

20.32 40.22

Valuation (TTM)

PE -8.35

PB 5.24

EV/EBITDA -7.40

Valuation (NTM)

Forward PE N/A

Forward PEG 3.79

Price Target $51

Cash Flow

FCF Yield -10.0%

SBC Adj. FCF Yield -11.6%

SBC Impact -16.3%

Margins

Gross Margin 84.7%

Operating Margin -809.7%

FCF Margin -654.9%

Growth (CAGR)

Revenue 3Y | 5Y 46.1% | 45.4%

Dil EPS 3Y | 5Y -37.7% | 7.6%

FCF 3Y | 5Y -75.0% | -27.0%

Returns

ROA -52.8%

ROE -59.4%

ROIC -62.7%

Financial Health

Net Cash

$290.97M

Current Ratio 7.69

Interest Coverage -4,856.02

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundament...

Sector Healthcare

Industry Biotechnology

Employees 170

IPO Date Jun 18, 2019

Website www.stoketherapeutics.com

Fiscal Year January - December

Full Company Profile

Latest News

19 days ago · gurufocus.com

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t

[url="]Stoke Therapeutics, Inc.[/url] (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with

1 month ago · defenseworld.net

Bank of America Corp DE Buys 336,931 Shares of Stoke Therapeutics, Inc. $STOK

Bank of America Corp DE lifted its stake in shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) by 163.4% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 543,095 shares of the company's stock after buying an additional 336,931 shares during the quarter. Bank

2 months ago · benzinga.com

These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results

Stoke Therapeutics Inc (NASDAQ:STOK) on Monday posted mixed results for the second quarter.

2 months ago · seekingalpha.com

Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript

2 months ago · zacks.com

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.4 per share a year ago.

2 months ago · marketbeat.com

Stoke Therapeutics Q2 Earnings Call Highlights

Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR study of zorevunersen in patients with Dravet syndrome remains on track for a data readout in the third quarter of 2027, following completion of enrollment ahead of the company's planned rolling new drug application submission.

2 months ago · businesswire.com

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the second quarter ended June 30, 2026, and provided business updates including progress of the global Pha.

2 months ago · businesswire.com

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that management will host a webcast and conference call for analysts and investors on Monday, August 3, 2026, at 4:30 p.m. ET,.

3 months ago · businesswire.com

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced the completion of enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen. Stoke plans to initiate a rolling.